Related Experiment Video
Updated: Jan 20, 2026

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal
Published on: January 26, 2019
New forms of induction of apoptosis in aggressive lymphoma using peptides that interrupt the RAS / RAF interaction
1Faculty of Medical Science, National University of La Plata, Argentina. gmarin2009@gmail.com
Interpretation:
RAS-RAF-MEK-ERK is a key pathway for apoptosis regulation in cancer cells. B-Raf-inhibitors such as PLX4032 peptide was developed by Institute Curie-Université Pierre et Marie Curie in order to induce apoptosis in cancer cells.
Objectives:
To demonstrate pro-apoptotic properties and survival outcome of EP2014/064243 peptide in murine aggressive lymphoma.
Material And Methodology:
BALBc mice with T-lymphoma were randomized assigned either in Group A (peptide+cyclophosphamide-CFM); Group B (peptides), Group C (CFM-control) or Control D (Cl-Na 0.9%-SF control group). Survival probability was calculated by Kaplan-Meier analysis. Apoptosis was detected using TUNEL technique. The protocol was approved by the Institutional Committee for Animal Care (CICUAL: T04-01-2015)
Results:
The median survival was 24 days (21.6-26.4) for placebo, 33 days (28.0-35.4) for the CFM monotherapy group, 33 (27.1-35.8) for the peptide group and 34 days (24,4-40) for CFM-peptide combined treatment (p<0.05). In lymph node tissue the mean TUNEL positive cells per field for each treatment group was 2, 12 and 13 and 35 for SF, CFM, peptide and combined therapy (p<0.05).
Conclusion:
These findings suggest that in murine aggressive lymphoma treated by an experimental peptide in addition with CFM, had an exponentially pro-apoptotic effect than CFM alone, suggesting that the peptide potentiated the anti-tumoural effect of CFM.
Insights
An experimental peptide significantly enhanced apoptosis and survival in mice with aggressive lymphoma when combined with cyclophosphamide (CFM). This peptide potentiates CFM
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The RAS-RAF-MEK-ERK pathway is crucial for regulating apoptosis in cancer cells.
- B-Raf inhibitors, like the PLX4032 peptide, are developed to induce apoptosis in cancer cells.
Purpose of the Study:
- To evaluate the pro-apoptotic properties and survival outcomes of the EP2014/064243 peptide in a murine model of aggressive lymphoma.
- To assess the combined effect of the peptide and cyclophosphamide (CFM) on lymphoma progression.
Main Methods:
- BALB/c mice with T-lymphoma were randomized into four groups: peptide + CFM, peptide alone, CFM alone, and saline control.
- Survival probability was analyzed using Kaplan-Meier analysis.
- Apoptosis was quantified using the TUNEL assay.
Main Results:
- The combination of EP2014/064243 peptide and CFM significantly increased median survival compared to CFM monotherapy (34 vs. 33 days).
- The peptide alone also showed a survival benefit (33 days) compared to the control group.
- TUNEL assay revealed a significantly higher number of apoptotic cells in lymph node tissue for the peptide and combined treatment groups compared to CFM alone and control.
Conclusions:
- The experimental peptide demonstrates significant pro-apoptotic effects in murine aggressive lymphoma.
- Combining the peptide with cyclophosphamide (CFM) potentiates the anti-tumoural effect, leading to improved survival outcomes.
- The peptide enhances the efficacy of CFM, suggesting a synergistic therapeutic potential.
Related Concept Videos
Aggression
The Ras Gene
Ras is a...
Apoptosis
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Peptide Bonds
Secondary Motives: Affiliation Motivation and Aggression Motivation

